Navigation Links
Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members

SAN JOSE, Calif., Nov. 11 /PRNewswire-USNewswire/ -- The CPF today announced that the Pulmonary Fibrosis Research Enhancement Act (PFREA) (H.R. 6567) - which would authorize $16 million in new federal funding for pulmonary fibrosis (PF) research - has now gained the support of 27 Members of the U.S. House of Representatives.

PFREA is first of its kind legislation to improve research and awareness of pulmonary fibrosis, a terminal lung disease with no known cause, no FDA approved treatment and no cure. (For more information on PF, visit The PFREA is expected to be re-introduced in the 111th Congress in early 2009. However, additional Members of Congress could be added on as co-sponsors in the current Congress if there is a lame duck Congressional session.

"We are pleased to see the Pulmonary Fibrosis Research Enhancement Act gaining momentum. This bill is critical to finding treatments and saving lives from this devastating disease," said Mishka Michon, Chief Executive Officer of the CPF. "We are thankful for the leadership Brian Baird and Mike Castle have given to this effort."

The PFREA was originally introduced in Congress on July 22, 2008 by Representative Brian Baird (D-WA) and Representative Mike Castle (R-DE). Congressman Baird lost his father to pulmonary fibrosis, and Congressman Castle lost his brother and sister to the devastating disease. A substantial portion of the $16 million authorization would be used to establish a comprehensive national registry of PF patients. The Act would also:

-- Mandate the creation of a National PF Action Plan, in conjunction with

the National Institutes of Health (NIH) and the Centers for Disease

Control (CDC), which would focus on strategies to improve public

awareness of PF, and accelerate patient and medical education

strategies. The Action Plan would be provided to the Director of the

NIH within one year of the Act's passage.

-- Establish a National PF Advisory Board, which would make recommendations

to the NIH and CDC concerning the structure and management of a PF

patient registry. The goal of the registry would be to improve

understanding of the cause(s) and progression of PF, improve standards

of care, accelerate research, and develop new therapies sooner.

-- Establish a National Summit on PF, to foster collaboration between

Federal Agencies, researchers, patients and advocates to identify new

approaches to research and treat PF. The Summit would be held every

three years.

To view the legislation in its entirety, please visit and type in "Pulmonary Fibrosis Research Enhancement Act" in the search box for bills.

To date, the following Members of Congress have agreed to co-sponsor H.R. 6567:

-- Thomas Allen - Maine

-- Rob Bishop - Utah

-- Earl Blumenauer - Oregon

-- Dennis Cardoza - California

-- Mike Castle - Delaware

-- Nathan Deal - Georgia

-- Diana DeGette - Colorado

-- Jim Gerlach - Pennsylvania

-- Virgil Goode - Virginia

-- Bob Goodlatte - Virginia

-- Bart Gordan - Tennessee

-- Jane Harman- California

-- Marcy Kaptur - Ohio

-- Mark Kirk - Illinois

-- Tom Latham - Louisiana

-- Steven LaTourette - Ohio

-- Zoe Lofgen - California

-- Jim Marshall - Georgia

-- Bill Pascrell - New Jersey

-- David Price - North Carolina

-- Jackie Speier - California

-- John Tierney - Massachusetts

-- Henry Waxman - California

-- Peter Welch - Vermont

-- Robert Wexler - Florida

-- Frank Wolf - Virginia

-- C.W. "Bill" Young - Florida

The CPF is actively advocating for the Bill's passage, and is asking its 17,000 members, and all those who are affected by PF, to voice their support for HR 6567 by visiting and becoming a CPF advocate. By joining the ACT campaign, you will become part of an army of volunteers who are contacting Congress, national health policymakers and the media to educate them about the PF. Every three months, members will receive free the CPF's ACT Action Alert, a newsletter detailing the advocacy efforts and outlining ways you can help. The CPF's advocacy program allows you to easily contact your Member of Congress immediately to voice your support. For further information, please visit the CPF at, call us at 888-222-8541, or email us at

About Pulmonary Fibrosis (PF)

IPF is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 17,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit or call (888) 222-8541.

SOURCE Coalition for Pulmonary Fibrosis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
2. Women at Higher Risk for Pulmonary Hypertension
3. Cialis May Help Ease Pulmonary Hypertension
4. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
5. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
6. The U.S. Surgeon General Issues National Call-to-Action on Deep-Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
7. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
8. American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act
9. Simple Case Management Cuts Pulmonary Disease Admissions
10. A guided broncoscope achieves biopsy of 75 percent pulmonary nodules without puncture or surgery
11. COPD patients benefit more from pulmonary rehab in earlier stages
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: